Kanamycin A

Kanamycin in Kenya

Mechanism of Action:

Kanamycin works by interfering with protein synthesis. It binds to the 30S subunit of the bacterial ribosome. This results in incorrect alignment with the mRNA and eventually leads to a misread that causes the wrong amino acid to be placed into the peptide.

Drug Label Information | Brands:

Brands of Kanamycin in Kenya:

Dawa-cin®, Dawa
Kanamed , Medisel Kenya Ltd

Kanamycin is a mixture of three main components: kanamycin A, B, and C. Kanamycin A is the major component in kanamycin
Kanamycin was first isolated in 1957 by Hamao Umezawa from the bacterium Streptomyces kanamyceticus

INDICATIONS:

Kanamycin is indicated for short term treatment of bacterial infections caused by one or more of the following pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, and Acinetobacter species. In cases of serious infection when the causative organism is unknown, Kanamycin injection in conjunction with a penicillin– or cephalosporin-type drug may be given initially before obtaining results of susceptibility testing.

Kanamycin does not treat viral infections

CONTRAINDICATIONS:

Documented hypersensitivity

SIDE EFFECTS:

Serious side effects include ringing in the ears or loss of hearing, toxicity to kidneys, and allergic reactions to the drug.
Other side effects include:

Gastrointestinal effects
Nausea, vomiting, diarrhea

Musculoskeletal effects
Myasthenia gravis

Neurologic effects
Headache
Paresthesias
Blurring of vision
Neuromuscular blockade

Metabolic effects
Malabsorption syndrome